In 2017, Ipsen’s R&D expenditure totaled close to €266 million, representing more than 13.9% of Group sales.
Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules, including small molecules, neurotoxins and theranostics.
